Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

Autor: Ruth L Goodall, Sarah K Meredith, Andrew J Nunn, Adamu Bayissa, Anuj K Bhatnagar, Gay Bronson, Chen-Yuan Chiang, Francesca Conradie, Meera Gurumurthy, Bruce Kirenga, Nana Kiria, Daniel Meressa, Ronelle Moodliar, Gopalan Narendran, Nosipho Ngubane, Mohammed Rassool, Karen Sanders, Rajesh Solanki, S Bertel Squire, Gabriela Torrea, Bazarragchaa Tsogt, Elena Tudor, Armand Van Deun, I D Rusen, Oyunchimeg Adilaa, Sofia Alexandru, Katharine Bellenger, Jaclyn Bennet, Deborah Bennet, Priyanka Bindroo, Ghanshyam Borisagar, Claire Cook, Doljinsuren Dalai, Andrew Davis, Bouke de Jong, Wendy Dodds, Lynette Duckworth, Nonhlanhla Gahima, Belay Gebreegziabher, Anne Goldfeld, Mahmud Hanifa, Gareth Hughes, Ivan Kimuli, Jan Komrska, Nino Lomtadze, Brendan Murphy, Thando Mwelase, Joanitah Nalunjogi, Leena Patel, Irina Pirlog, Ishmael Qawiy, Mary Rauchenberger, Leen Rigouts, Carol Roach, Laura Rosu, Ezio Santos-Filho, Thirumaran Senguttuvan, Million Sisay, Rathinam Sridhar, Vignes Srinivasulu, Mekonnen Teferi, Helen Teklu, Narangarav Tsegeen, Odette van Amsterdam, Lisa White, Johanna Whitney, Chuluunbaatar Zagd

Publikováno v: Lancet (London, England). 400(10366)

The STREAM stage 1 trial showed that a 9-month regimen for the treatment of rifampicin-resistant tuberculosis was non-inferior to the 20-month 2011 WHO-recommended regimen. In STREAM stage 2, we aimed to compare two bedaquiline-containing regimens wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c955b8f2fa408406f893ed06e640c853
https://pubmed.ncbi.nlm.nih.gov/36375483